Ono Pharmaceutical Co., Ltd. (4528.T)
JPY 1611.0
(-1.2%)
JPY 1611.0
(-1.2%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 502.67 Billion | 447.18 Billion | 361.36 Billion | 309.28 Billion | 292.42 Billion | 288.63 Billion |
| Cost of Revenue | 127.12 Billion | 110.06 Billion | 93.51 Billion | 85.57 Billion | 79.06 Billion | 83.82 Billion |
| Gross Profit | 375.54 Billion | 337.12 Billion | 267.85 Billion | 223.71 Billion | 213.35 Billion | 204.8 Billion |
| Operating Expenses | 212.44 Billion | 195.16 Billion | 164.65 Billion | 125.38 Billion | 135.86 Billion | 142.79 Billion |
| Selling, General and Administrative Expenses | 100.27 Billion | 89.48 Billion | 77.05 Billion | 69.23 Billion | 67.67 Billion | 70.03 Billion |
| Research and Development Expenses | 112.17 Billion | 95.34 Billion | 75.87 Billion | 62.38 Billion | 66.49 Billion | 70 Billion |
| Other Expenses | -1 Million | - | 11.71 Billion | -6.23 Billion | 1.69 Billion | 2.75 Billion |
| Cost and Expenses | 339.56 Billion | 305.22 Billion | 258.16 Billion | 210.95 Billion | 214.92 Billion | 226.62 Billion |
| Operating Income | 163.1 Billion | 141.96 Billion | 103.19 Billion | 98.33 Billion | 77.49 Billion | 62.01 Billion |
| Interest Expense | 229 Million | 913 Million | 874 Million | 137 Million | 845 Million | 150 Million |
| Income Tax Expense | 35.69 Billion | 30.61 Billion | 24.34 Billion | 25.39 Billion | 19.8 Billion | 13.46 Billion |
| Earnings before Tax | 163.73 Billion | 143.53 Billion | 105.02 Billion | 100.89 Billion | 79.69 Billion | 65.14 Billion |
| Net Income | 127.97 Billion | 112.72 Billion | 80.51 Billion | 75.42 Billion | 59.7 Billion | 51.53 Billion |
| Earnings Per Share Basic | 266.61 | 230.85 | 162.19 | 151.11 | 118.47 | 100.25 |
| Earnings Per Share Diluted | 266.60 | 230.79 | 162.16 | 151.09 | 118.45 | 100.24 |
| Weighted Average Shares Outstanding | 480 Million | 488.3 Million | 496.45 Million | 499.13 Million | 503.97 Million | 514.12 Million |
| Weighted Average Shares Outstanding (Diluted) | 480.03 Million | 488.35 Million | 496.52 Million | 499.2 Million | 504.04 Million | 514.17 Million |
| Gross Margin | 0.75 | 0.75 | 0.74 | 0.72 | 0.73 | 0.71 |
| EBIT Margin | 0.35 | 0.36 | 0.34 | 0.38 | 0.32 | 0.26 |
| Profit Margin | 0.25 | 0.25 | 0.22 | 0.24 | 0.20 | 0.18 |
| EBITDA | 178.43 Billion | 167.49 Billion | 128.53 Billion | 114.54 Billion | 93.99 Billion | 74.2 Billion |
| Earnings Before Tax Margin | 0.32 | 0.32 | 0.29 | 0.32 | 0.26 | 0.21 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 122.66 Billion | 117.67 Billion | 502.67 Billion | 112.76 Billion | 131.19 Billion | 138.69 Billion |
| Cost of Revenue | 27.2 Billion | 29.67 Billion | 127.12 Billion | 31.66 Billion | 30.69 Billion | 34.59 Billion |
| Gross Profit | 95.45 Billion | 88 Billion | 375.54 Billion | 81.1 Billion | 100.49 Billion | 104.1 Billion |
| Operating Expenses | 70.48 Billion | 57.31 Billion | 212.44 Billion | 62.65 Billion | 52.9 Billion | 48.41 Billion |
| Selling, General and Administrative Expenses | 30.53 Billion | 27.88 Billion | - | 26.97 Billion | 25.69 Billion | 24.12 Billion |
| Research and Development Expenses | 39.94 Billion | 28.85 Billion | - | 35.68 Billion | 27.13 Billion | 24.78 Billion |
| Other Expenses | - | 571 Million | 459 Million | - | - | - |
| Cost and Expenses | 97.69 Billion | 86.98 Billion | 339.57 Billion | 94.32 Billion | 83.6 Billion | 83 Billion |
| Operating Income | 24.97 Billion | 30.69 Billion | 163.1 Billion | 18.44 Billion | 47.59 Billion | 55.68 Billion |
| Interest Expense | 3.44 Billion | 75 Million | 229 Million | - | 1.1 Billion | 20 Million |
| Income Tax Expense | 4.51 Billion | 8.47 Billion | 35.69 Billion | -988 Million | 11.9 Billion | 14.21 Billion |
| Earnings before Tax | 21.32 Billion | 33.31 Billion | 163.73 Billion | 16.44 Billion | 47.99 Billion | 56.91 Billion |
| Net Income | 16.84 Billion | 24.79 Billion | 127.97 Billion | 17.43 Billion | 36.05 Billion | 42.67 Billion |
| Earnings Per Share Basic | 35.87 | 52.79 | - | 37.54 | 75.77 | 88.18 |
| Earnings Per Share Diluted | 35.87 | 52.75 | - | 37.50 | 75.77 | 88.18 |
| Weighted Average Shares Outstanding | 469.71 Million | 470.02 Million | 480 Million | 472.57 Million | 475.83 Million | 483.93 Million |
| Weighted Average Shares Outstanding (Diluted) | 469.71 Million | 470.02 Million | 480.03 Million | 472.44 Million | 475.83 Million | 483.93 Million |
| Gross Margin | 0.78 | 0.75 | 0.75 | 0.72 | 0.77 | 0.75 |
| EBIT Margin | 0.24 | 0.30 | - | 0.21 | 0.41 | 0.44 |
| Profit Margin | 0.14 | 0.21 | 0.25 | 0.15 | 0.27 | 0.31 |
| EBITDA | 29.38 Billion | 35.06 Billion | - | 23.16 Billion | 53.44 Billion | 61.49 Billion |
| Earnings Before Tax Margin | 0.20 | 0.26 | 0.32 | 0.16 | 0.36 | 0.40 |
002490
3900
600312
VEXT
000967
9059